A Phase II Study to Prevent Radiation-induced Rectal Injury With Lovastatin
Conclusions:
The primary endpoint of the study was not met. Lovastatin, as administered in this trial, did not reduce the incidence of grade 2 or higher rectal toxicity compared with historical controls.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Colorectal Cancer | Gastroenterology | History of Medicine | Lovastatin | Prostate Cancer | Radiation Therapy | Study | Toxicology